1 |
National Cancer Information Center. Cancer registry [Internet]. Goyang: National Cancer Information Center, c2012 [cited 2012 July 22]. Available from: http://www. cancer.go.kr/cms/statics/ incidence/index.html.
|
2 |
Cuschieri A, Weeden S, Fielding J, et al. Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial: Surgical Co-operative Group. Br J Cancer 1999;79:1522-1530.
DOI
ScienceOn
|
3 |
Bonenkamp JJ, Songun I, Hermans J, et al. Randomised comparison of morbidity after D1 and D2 dissection for gastric cancer in 996 Dutch patients. Lancet 1995;345: 745-748.
DOI
ScienceOn
|
4 |
Cuschieri A, Fayers P, Fielding J, et al. Postoperative morbidity and mortality after D1 and D2 resections for gastric cancer: preliminary results of the MRC randomised controlled surgical trial: the Surgical Cooperative Group. Lancet 1996;347:995-999.
DOI
ScienceOn
|
5 |
Bonenkamp JJ, Hermans J, Sasako M, et al. Extended lymph-node dissection for gastric cancer. N Engl J Med 1999;340:908-914.
DOI
ScienceOn
|
6 |
Degiuli M, Sasako M, Calgaro M, et al. Morbidity and mortality after D1 and D2 gastrectomy for cancer: interim analysis of the Italian Gastric Cancer Study Group (IGCSG) randomised surgical trial. Eur J Surg Oncol 2004;30: 303-308.
DOI
ScienceOn
|
7 |
Degiuli M, Sasako M, Ponti A, Calvo F. Survival results of a multicentre phase II study to evaluate D2 gastrectomy for gastric cancer. Br J Cancer 2004;90:1727-1732.
|
8 |
Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001;345:725-730.
DOI
ScienceOn
|
9 |
Wu CW, Hsiung CA, Lo SS, et al. Nodal dissection for patients with gastric cancer: a randomised controlled trial. Lancet Oncol 2006;7:309-315.
DOI
ScienceOn
|
10 |
Hermans J, Bonenkamp JJ, Boon MC, et al. Adjuvant therapy after curative resection for gastric cancer: meta-analysis of randomized trials. J Clin Oncol 1993;11:1441- 1447.
|
11 |
Earle CC, Maroun JA. Adjuvant chemotherapy after curative resection for gastric cancer in non-Asian patients: revisiting a meta-analysis of randomised trials. Eur J Cancer 1999; 35:1059-1064.
DOI
ScienceOn
|
12 |
Mari E, Floriani I, Tinazzi A, et al. Efficacy of adjuvant chemotherapy after curativeresection for gastric cancer: a meta-analysis of published randomised trials: a study of the GISCAD (Gruppo Italiano per lo Studio dei Carcinomi dell'Apparato Digerente). Ann Oncol 2000;11:837-843.
DOI
ScienceOn
|
13 |
Janunger KG, Hafström L, Glimelius B. Chemotherapy in gastric cancer: a review and updated meta-analysis. Eur J Surg 2002;168:597-608.
DOI
ScienceOn
|
14 |
Panzini I, Gianni L, Fattori PP, et al. Adjuvant chemotherapy in gastric cancer: a meta-analysis of randomized trials and a comparison with previous meta-analyses. Tumori 2002;88: 21-27.
|
15 |
Sakamoto J, Tsuburaya A, Morita S, et al. Adjuvant chemotherapy with tegafur/uracil (UFT) for gastric cancer: ameta-analysis of centrally randomized clinical trials. J Clin Oncol 200624(18 Suppl):S4033.
|
16 |
Bajetta E, Floriani I, Di Bartolomeo M, et al. Intergroup Trial of Adjuvant Chemotherapy in Adenocarcinoma of the Stomach (ITACA-S) trial: comparison of a sequential treatment with irinotecan (CPT-11) plus 5-fluorouracil (5-FU)/folinic acid (LV) followed by docetaxel and cisplatin versus a 5-FU/LV regimen as postoperative treatment for radically resected gastric cancer. J Clin Oncol 2012;30(18 Suppl):LBA4001.
|
17 |
Nakajima T, Nashimoto A, Kitamura M, et al. Adjuvant mitomycin and fluorouracil followed by oral uracil plus tegafur in serosa-negative gastric cancer: a randomised trial: Gastric Cancer Surgical Study Group. Lancet 1999;354: 273-277.
DOI
ScienceOn
|
18 |
Miyashiro I, Furukawa H, Sasako M, et al. Randomized clinical trial of adjuvant chemotherapy with intraperitoneal and intravenous cisplatin followed by oral fluorouracil (UFT) in serosa-positive gastric cancer versus curative resection alone: final results of the Japan Clinical Oncology Group trial JCOG9206-2. Gastric Cancer 2011;14:212-218.
DOI
ScienceOn
|
19 |
Fuchs CS, Tepper JE, Niedzwiecki D, et al. Postoperative adjuvant chemoradiation for gastric or gastroesophageal junction (GEJ) adenocarcinoma using epirubicin, cisplatin, and infusional (CI) 5-FU (ECF) before and after CI 5-FU and radiotherapy (CRT) compared with bolus 5-FU/LV before and after CRT: intergroup trial CALGB 80101. J Clin Oncol 2011;29(15 Suppl):S4003.
|
20 |
Lee J, Lim do H, Kim S, et al. Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial. J Clin Oncol 2012;30:268-273.
DOI
ScienceOn
|
21 |
Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006;355:11-20.
DOI
ScienceOn
|
22 |
Sakuramoto S, Sasako M, Yamaguchi T, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 2007;357:1810-1820.
DOI
ScienceOn
|
23 |
Sasako M, Sakuramoto S, Katai H, et al. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol 2011;29:4387-4393.
DOI
ScienceOn
|
24 |
Kang YK, Ryoo BY, Chang HM, et al. Update of AMC 0101 study: a phase III trial of intraperitoneal cisplatin and early mitomycin-C plus long-term doxifluridine plus cisplatin (iceMFP) versus mitomycin-C plus short-term doxifluridine (Mf) as adjuvant chemotherapy for grossly serosa-positive advanced gastric cancer (NCT00296322). J Clin Oncol 2012;30(Suppl 4):S4.
|
25 |
Kang Y, Chang H, Zang D, et al. Postoperative adjuvant chemotherapy for grossly serosa-positive advanced gastric cancer: a randomized phase III trial of intraperitoneal cisplatin and early mitomycin-C plus long-term doxifluridine plus cisplatin (iceMFP) versus mitomycin-C plus short- term doxifluridine (Mf) (AMC 0101) (NCT00296322). J Clin Oncol 2008;26(15 Suppl):LBA4511.
|
26 |
Cirera L, Balil A, Batiste-Alentorn E, et al. Randomized clinical trial of adjuvant mitomycin plus tegafur in patients with resected stage III gastric cancer. J Clin Oncol 1999; 17:3810-3815.
|
27 |
Chang H, Kang Y, Min Y, et al.A randomized phase III trial comparing mitomycin-C plus short-term doxifluridine (Mf) versus mitomycin-C plus long-term doxifluridine plus cisplatin (MFP) after curative resection of advanced gastric cancer (AMC 0201) (NCT00296335). J Clin Oncol 2008;26 (15 Suppl):S4531.
|
28 |
Ryoo BY, Kang YK, Min YJ, et al. Update of AMC 0201 study: a randomized phase III trial comparing mitomycin-C plus short-term doxifluridine (Mf) versus mitomycin-C plus long-term doxifluridine plus cisplatin (MFP) after curative resection of advanced gastric cancer (NCT00296335). J Clin Oncol 2012;30(Suppl 4):S76.
|
29 |
Bang YJ, Kim YW, Yang HK, et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet 2012;379:315-321.
DOI
ScienceOn
|